A 29-percentage-point placebo-adjusted response rate at week 12 is not a number MoonLake’s competitors in hidradenitis suppurativa can easily dismiss. That delta, drawn from the MIRA trial and now formally accepted by the FDA as part of the label strategy for sonelokimab, positions the drug above every other HS therapy that has cleared an adequate, well-controlled trial — including AbbVie’s Humira and UCB’s bimekizumab. The pre-BLA meeting resolved every outstanding question, including CMC alignment, safety pooling, and the adolescent data strategy. MoonLake is not navigating uncertainty; it is executing a sequenced launch plan with a BLA submission locked for September 2026 and a commercial debut targeted for the second half of 2027.
The adolescent angle deserves more attention than it typically gets in HS coverage. FDA agreement to treat VELA-TEEN as final and pivotal at the time of BLA submission means a label covering patients aged 12 and above — and that triggers a Priority Review application. Priority Review, if granted, compresses the standard ten-month clock to six, pulling the approval decision well into 2027 and giving MoonLake a meaningful head start on commercial infrastructure before the broader IL-17 competition fully matures in the indication. Bimekizumab has the market now, but it does not have a pediatric label, and Humira’s biosimilar erosion in HS will accelerate regardless of which next-generation agent takes share.
The financial picture is deliberately constructed to avoid dilution under pressure. With $357.9 million in cash and $400 million in untapped Hercules debt, MoonLake’s runway extends through end-2027 — past BLA acceptance, through PDUFA, and into the commercial ramp. Q1 R&D spend of $54.5 million held essentially flat versus Q4 2025, signaling no unexpected trial overruns. The $6.3 million G&A spike was an accounting artifact from voluntary stock option cancellations, not operational drift. A company burning roughly $280 million annually against that capital base has a real buffer, not a manufactured one.
The single marker worth tracking is the Priority Review designation decision, expected by end of November 2026. A six-month review clock means a mid-2027 approval — before AbbVie can realistically launch any next-generation HS program. Denial of Priority Review extends the timeline by four months and narrows that competitive window considerably.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
